{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:52:57Z","timestamp":1793652777358,"version":"4.5.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":293,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020098","name":"Innovative Health Initiative","doi-asserted-by":"publisher","award":["101172693"],"award-info":[{"award-number":["101172693"]}],"id":[{"id":"10.13039\/100020098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["NAM Journal"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.namjnl.2025.100065","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T15:24:47Z","timestamp":1761146687000},"page":"100065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Transitional initiatives for advancing the phasing out of the use of animals for drug and chemical safety testing: The IHI VICT3R project for reducing the use of animals by implementing virtual control groups"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7534-7661","authenticated-orcid":false,"given":"Ferran","family":"Sanz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Matyjasiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Orihuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen M.","family":"Pike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2428-5245","authenticated-orcid":false,"given":"Inari","family":"Soininen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3628-6317","authenticated-orcid":false,"given":"Frank","family":"Bringezu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2264-7852","authenticated-orcid":false,"given":"Olga","family":"Valverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Vinken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1790-4404","authenticated-orcid":false,"given":"Janette","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4258-3008","authenticated-orcid":false,"given":"Thomas","family":"Steger-Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.namjnl.2025.100065_bib0001","series-title":"Silico Methods for Predicting Drug Toxicity. Methods in Molecular Biology","article-title":"Adverse outcome pathways as versatile tools in liver toxicity testing","volume":"2425","author":"Arnesdotter","year":"2022"},{"key":"10.1016\/j.namjnl.2025.100065_bib0002","first-page":"647","article-title":"A proof-of-concept rat toxicity study highlights the potential utility and challenges of virtual control groups","volume":"41","author":"Andaya","year":"2024","journal-title":"ALTEX"},{"key":"10.1016\/j.namjnl.2025.100065_bib0003","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/d41573-025-00024-y","article-title":"A new European platform for advancing regulatory science research","volume":"24","author":"Barbier","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.namjnl.2025.100065_bib0004","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-3-319-33826-2_3","article-title":"Regulatory acceptance of alternative methods in the development and approval of pharmaceuticals","volume":"856","author":"Beken","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.namjnl.2025.100065_bib0005","article-title":"ASPIS definition of new approach methodologies","author":"Colbourne","year":"2025","journal-title":"Environ. Toxicol. Chem. In Press."},{"key":"10.1016\/j.namjnl.2025.100065_bib0006","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13321-024-00925-x","article-title":"PretoxTM: a text mining system for extracting treatment-related findings from preclinical toxicology reports","volume":"17","author":"Corvi","year":"2025","journal-title":"J. Cheminform."},{"key":"10.1016\/j.namjnl.2025.100065_bib0007","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1152\/physrev.00043.2023","article-title":"Best practices for data management and sharing in experimental biomedical research","volume":"104","author":"Cunha-Oliveira","year":"2024","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.namjnl.2025.100065_bib0008","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.comtox.2018.06.001","article-title":"Principles underpinning the use of new methodologies in the risk assessment of cosmetic ingredients","volume":"7","author":"Dent","year":"2018","journal-title":"Comput. Toxicol."},{"key":"10.1016\/j.namjnl.2025.100065_bib0009","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/d41573-025-00053-7","article-title":"New approach methodologies: EU regulatory horizons","volume":"24","author":"Edwards","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.namjnl.2025.100065_bib0010","unstructured":"EMA, 2014. Qualification of novel methodologies for drug development: guidance to applicants: guidance to applicants."},{"key":"10.1016\/j.namjnl.2025.100065_bib0011","unstructured":"EMA, 2024. Reflection paper on the current regulatory testing 5 requirements for medicinal products for human use and 6 opportunities for implementation of the 3Rs. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-reflection-paper-current-regulatory-testing-requirements-medicinal-products-human-use-opportunities-implementation-3rs-revision-1_en.pdf."},{"key":"10.1016\/j.namjnl.2025.100065_bib0012","article-title":"Commission acts to accelerate phasing out of animal testing in response to a European Citizens","year":"2023","journal-title":"Initiative"},{"key":"10.1016\/j.namjnl.2025.100065_bib0013","unstructured":"European Commission, 2023b Reform of the EU pharmaceutical legislation. https:\/\/health.ec.europa.eu\/medicinal-products\/legal-framework-governing-medicinal-products-human-use-eu\/reform-eu-pharmaceutical-legislation_en."},{"key":"10.1016\/j.namjnl.2025.100065_bib0014","unstructured":"European Council, 2024. Summary report on the statistics on the use of animals for scientific purposes in the Member States of the European Union and Norway in 2022. Brussels, 19.7.2024 SWD (2024) 185 final. https:\/\/data.consilium.europa.eu\/doc\/document\/ST-12496-2024-INIT\/en\/pdf."},{"key":"10.1016\/j.namjnl.2025.100065_bib0015","first-page":"33","article-title":"Directive 2010\/63\/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes","volume":"276","year":"2010","journal-title":"OJL"},{"key":"10.1016\/j.namjnl.2025.100065_bib0016","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s43856-022-00209-1","article-title":"Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology","volume":"2","author":"Ewart","year":"2022","journal-title":"Commun. Med. (London)"},{"key":"10.1016\/j.namjnl.2025.100065_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1087057115594589","article-title":"A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm","volume":"21","author":"Fermini","year":"2016","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.namjnl.2025.100065_bib0020","doi-asserted-by":"crossref","DOI":"10.1038\/nature.2013.14416","article-title":"Scientists losing data at a rapid rate","author":"Gibney","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.namjnl.2025.100065_bib0021","first-page":"282","article-title":"Toward implementing virtual control groups in nonclinical safety studies","volume":"41","author":"Golden","year":"2024","journal-title":"ALTEX"},{"key":"10.1016\/j.namjnl.2025.100065_bib0022","first-page":"395","article-title":"The benefits of validation of methods for toxicity testing outweigh its costs","volume":"41","author":"Gourmelon","year":"2024","journal-title":"ALTEX"},{"key":"10.1016\/j.namjnl.2025.100065_bib0023","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1177\/01926233231224805","article-title":"Toxicologic pathology forum opinion piece: use of virtual control groups in nonclinical toxicity studies: the anatomic pathology perspective","volume":"51","author":"Grevot","year":"2023","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.namjnl.2025.100065_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1142534","article-title":"Hurdles and signposts on the road to virtual control groups-A case study illustrating the influence of anesthesia protocols on electrolyte levels in rats","volume":"14","author":"Gurjanov","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.namjnl.2025.100065_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105592","article-title":"Replacing concurrent controls with virtual control groups in rat toxicity studies","volume":"148","author":"Gurjanov","year":"2024","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.namjnl.2025.100065_bib0026","first-page":"660","article-title":"The road to virtual control groups and the importance of proper body-weight selection","volume":"41","author":"Gurjanov","year":"2024","journal-title":"ALTEX"},{"key":"10.1016\/j.namjnl.2025.100065_bib0027","doi-asserted-by":"crossref","first-page":"5778","DOI":"10.1038\/s41467-021-26103-3","article-title":"A primer for academic entrepreneurs on academic-industrial partnerships","volume":"12","author":"Hait","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.namjnl.2025.100065_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105683","article-title":"Endeavours made by trade associations, pharmaceutical companies and regulators in the replacement, reduction and refinement of animal experimentation in safety testing of pharmaceuticals","volume":"152","author":"Harrell","year":"2024","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.namjnl.2025.100065_bib0029","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/ilar\/ilu042","article-title":"Meta-analyses of animal studies: an introduction of a valuable instrument to further improve healthcare","volume":"55","author":"Hooijmans","year":"2014","journal-title":"ILAR J."},{"key":"10.1016\/j.namjnl.2025.100065_bib0030","series-title":"Alternatives to Animal Testing","article-title":"Guidance on the use of alternative test methods for the safety assessment of cosmetics and quasi-drugs","author":"Kojima","year":"2019"},{"key":"10.1016\/j.namjnl.2025.100065_bib0031","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1007\/s00204-017-2045-3","article-title":"Adverse outcome pathways: opportunities, limitations and open questions","volume":"91","author":"Leist","year":"2017","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.namjnl.2025.100065_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105733","article-title":"Statistical applications of virtual control groups to nonrodent animal toxicity studies: an initial evaluation","volume":"154","author":"Li","year":"2024","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.namjnl.2025.100065_bib0033","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/15376510701857320","article-title":"In silico tools for sharing data and knowledge on toxicity and metabolism: derek for windows, meteor, and vitic","volume":"18","author":"Marchant","year":"2008","journal-title":"Toxicol. Mech. Methods"},{"key":"10.1016\/j.namjnl.2025.100065_bib0034","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41684-024-01335-0","article-title":"A minimal metadata set (MNMS) to repurpose nonclinical in vivo data for biomedical research","volume":"53","author":"Moresis","year":"2024","journal-title":"Lab. Anim. (NY)."},{"key":"10.1016\/j.namjnl.2025.100065_bib0036","series-title":"Guidance Document On the Validation and International Acceptance of New Or Updated Test Methods For Hazard Assessment","year":"2005"},{"key":"10.1016\/j.namjnl.2025.100065_bib0037","series-title":"OECD Series on Testing and Assessment","article-title":"The adverse outcome pathway for skin sensitisation initiated by covalent binding to proteins","year":"2014"},{"key":"10.1016\/j.namjnl.2025.100065_bib0038","series-title":"Test No. 442D: In Vitro Skin Sensitisation: Assays Addressing the Adverse Outcome Pathway Key Event on Keratinocyte Activation, OECD Guidelines for the Testing of Chemicals","year":"2024"},{"key":"10.1016\/j.namjnl.2025.100065_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105632","article-title":"Points to consider regarding the use and implementation of virtual controls in nonclinical general toxicology studies","volume":"150","author":"Palazzi","year":"2024","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.namjnl.2025.100065_bib0040","doi-asserted-by":"crossref","DOI":"10.1523\/JNEUROSCI.0381-24.2024","article-title":"A perspective on neuroscience data standardization with neurodata without borders","volume":"44","author":"Pierr\u00e9","year":"2024","journal-title":"J. Neurosci."},{"key":"10.1016\/j.namjnl.2025.100065_bib0042","doi-asserted-by":"crossref","first-page":"25","DOI":"10.14573\/altex.1411011","article-title":"Integrated testing strategies (ITS) for safety assessment","volume":"32","author":"Rovida","year":"2015","journal-title":"ALTEX"},{"key":"10.1016\/j.namjnl.2025.100065_bib0043","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/d41573-023-00099-5","article-title":"eTRANSAFE: data science to empower translational safety assessment","volume":"22","author":"Sanz","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.namjnl.2025.100065_bib0044","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev-biodatasci-103123-095506","article-title":"Integrative data science in drug safety research: experiences, challenges, and perspectives","volume":"8","author":"Sanz","year":"2025","journal-title":"Annu. Rev. Biomed. Data Sci."},{"key":"10.1016\/j.namjnl.2025.100065_bib0045","first-page":"1","article-title":"Potential issues associated with the introduction of virtual control groups into non-clinical toxicology studies","volume":"6","author":"Sato","year":"2024","journal-title":"Transl. Reg. Sci."},{"key":"10.1016\/j.namjnl.2025.100065_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.envint.2023.108082","article-title":"New approach methodologies in human regulatory toxicology: not if, but how and when!","volume":"178","author":"Schmeisser","year":"2023","journal-title":"Environ. Int."},{"key":"10.1016\/j.namjnl.2025.100065_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104328","article-title":"Opportunities and insights from pharmaceutical companies on the current use of new approach methodologies in nonclinical safety assessment","volume":"30","author":"Shenton","year":"2025","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.namjnl.2025.100065_bib0048","first-page":"343","article-title":"Introducing the concept of virtual control groups into preclinical toxicology testing","volume":"37","author":"Steger-Hartmann","year":"2020","journal-title":"ALTEX"},{"key":"10.1016\/j.namjnl.2025.100065_bib0049","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1177\/01926233241303906","article-title":"IHI VICT3R: developing and implementing virtual control groups to reduce animal use in toxicology research","volume":"53","author":"Steger-Hartmann","year":"2025","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.namjnl.2025.100065_bib0050","first-page":"538","article-title":"Virtual control groups in non-clinical toxicology \u2013 a replicability challenge","volume":"42","author":"Steger-Hartmann","year":"2025","journal-title":"ALTEX"},{"key":"10.1016\/j.namjnl.2025.100065_bib0051","first-page":"503","article-title":"Trends in the use of animals and non-animal methods over the last 20 years","volume":"41","author":"Taylor","year":"2024","journal-title":"ALTEX"},{"key":"10.1016\/j.namjnl.2025.100065_bib0052","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s12021-021-09533-8","article-title":"Promoting FAIR data through community-driven agile design: the open data commons for spinal cord injury (odc-sci.org)","volume":"20","author":"Torres-Esp\u00edn","year":"2022","journal-title":"Neuroinformatics"},{"key":"10.1016\/j.namjnl.2025.100065_bib0053","doi-asserted-by":"crossref","first-page":"e2479","DOI":"10.1002\/bdr2.2479","article-title":"Perspectives on implementing virtual control groups in developmental and reproductive toxicity studies","volume":"117","author":"Wise","year":"2025","journal-title":"Birth. Defects Res."},{"key":"10.1016\/j.namjnl.2025.100065_bib0054","author":"World Health Organization"}],"container-title":["NAM Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050620425000600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3050620425000600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:05:54Z","timestamp":1780549554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3050620425000600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":50,"alternative-id":["S3050620425000600"],"URL":"https:\/\/doi.org\/10.1016\/j.namjnl.2025.100065","relation":{},"ISSN":["3050-6204"],"issn-type":[{"value":"3050-6204","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transitional initiatives for advancing the phasing out of the use of animals for drug and chemical safety testing: The IHI VICT3R project for reducing the use of animals by implementing virtual control groups","name":"articletitle","label":"Article Title"},{"value":"NAM Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.namjnl.2025.100065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100065"}}